New immune cell therapy targets aggressive blood cancer
NCT ID NCT07164560
Summary
This study is testing a new type of CAR-T cell therapy, called TRBC1/2 CAR-T, for adults whose peripheral T-cell lymphoma has come back or hasn't responded to at least one prior treatment. The main goals are to find a safe dose and see if the therapy can shrink or eliminate the cancer. This is an early-phase trial that will enroll about 45 participants to monitor safety and initial effectiveness for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY/RECURRENT PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Affiliated Hospital,School of Medicine,Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.